Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.(2019).
A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.(2019).
Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia.Biol Blood Marrow Transplant.(2018).
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Cancer.(2016).
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Cancer.(2016).
Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.Biol Blood Marrow Transplant.(2016).
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.(2016).
Stem cell transplantation outcomes in lymphoblastic lymphoma.Leuk Lymphoma1-6.(2016).